VEGFA and neoplasm: Hypoxia further promotes angiogenesis, epithelial-mesenchymal transition, and tumor metastasis through vascular endothelial growth factor A (VEGFA) or HIF-1, exacerbating hypoxia and immunosuppression, and patients are less likely to benefit from this therapy (86, 87).